All Outputs (2)

Investigating prescribers' experiences of direct-acting oral anticoagulants for the management of nonvalvular atrial fibrillation. (2020)
Thesis
GENERALOVA, D. 2020. Investigating prescribers' experiences of direct-acting oral anticoagulants for the management of nonvalvular atrial fibrillation. Robert Gordon University, PhD thesis. Hosted on OpenAIR [online]. Available from: https://doi.org/10.48526/rgu-wt-1447131

Direct-acting oral anticoagulants (DOACs) have relatively recently been licensed for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation (AF) and have replaced warfarin as the first line agent of choice. The aim... Read More about Investigating prescribers' experiences of direct-acting oral anticoagulants for the management of nonvalvular atrial fibrillation..

Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation. (2020)
Journal Article
GENERALOVA, D., CUNNINGHAM, S., LESLIE, S.J., RUSHWORTH, G.F., MCIVER, L. and STEWART, D. 2020. Prescribers' perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation. Pharmacy practice [online], 18(2), article ID 1936. Available from: https://doi.org/10.18549/PharmPract.2020.2.1936

There is an acknowledged lack of robust and rigorous research focusing on the perspectives of those prescribing direct acting oral anticoagulants (DOACs) for non-valvular atrial fibrillation (AF). The objective was to describe prescribers’ experience... Read More about Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation..